RBC Capital Markets has lowered its price target for BioMarin Pharmaceutical to $60 from $62, while maintaining a Sector Perform rating. This adjustment is a direct consequence of BioMarin's Q3 2026 earnings report, which included a downward revision to its 2026 financial guidance, indicating potential headwinds for the company's future performance.
RBC Capital Markets reduced its price target for BioMarin Pharmaceutical (BMRN) from $62 to $60, while keeping its 'Sector Perform' rating. This decision directly stems from BioMarin's recently reported Q3 2026 earnings, which included a downward revision to its 2026 financial guidance. This guidance cut is a significant event as it signals a less optimistic outlook for the company's future financial performance, impacting investor sentiment and potentially leading to short-term stock price pressure. For traders, this indicates a potential negative sentiment shift, and while the rating remained 'Sector Perform', the lowered price target suggests a more cautious approach to BMRN's valuation given the updated financial projections.